Single-Agent Ifosfamide in Patients with Recurrent Neuroblastoma (Ensg Study 2): Pediatric Hematology and Oncology: Vol 4, No 2

Views

CrossRef citations to date

Altmetric

Abstract

Twenty-five patients with progressive or recurrent neuroblastoma were treated with single-agent ifosfamide. In 2 of 10 relapsing patients, an objective response was observed. If ifosfamide is administered in a dose of 3000 mg/m² for 2 days every 3 weeks, a response can be expected in 8% of the cases.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Single-Agent Ifosfamide in Patients with Recurrent Neuroblastoma (Ensg Study 2)

Information for

Open access

Opportunities

Help and information

Single-Agent Ifosfamide in Patients with Recurrent Neuroblastoma (Ensg Study 2)

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature